Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic HBV

服务不足的亚裔美国人慢性乙型肝炎患者长期坚持监测/治疗

基本信息

  • 批准号:
    10015225
  • 负责人:
  • 金额:
    $ 24.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-19 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Full Research Project 1 – Liver Cancer Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic HBV TU FCCC: Grace X. Ma, PhD (Co-Leader) and Nestor Esnaola, MD, MPH (Co-Leader, URM ESI) HC: Sarit A. Golub, PhD (Co-Leader) and Chibuzo Enemchukwu, MD (Co-Leader, URM ESI) Although Asian Americans make up 6% of total U.S. population, they account for over 50% of Americans with chronic hepatitis B (CHB), which is associated with 75% of hepatocellular carcinoma (HCC), the most common type of liver cancer. Asian Americans as a liver cancer disparity population are 8-13 times more likely to develop liver cancer with 60% higher death rate than non-Hispanic whites (NHWs). Research indicates that blood tests every six months and an abdominal ultrasound every 12 months, combined with antiviral treatment (e.g. entecavir or tenofovir) when appropriate, is the gold standard of care to reduce the risk of liver disease (including HCC). However, adherence to monitoring and antiviral treatment guidelines among Asian American patients with CHB is as low as 40% to 53%. Poor healthcare access and significant cultural barriers may prevent long-term adherence to monitoring and optimal treatment, placing Asian Americans at a disproportionately high risk for HCC and increased healthcare costs. Building on previous studies on a patient navigator-led intervention to improve monitoring and care among noncompliant Asian American with CHB, conducted by our established academic-clinical-community research team, we developed and pilot tested a virtual patient navigation toolkit system (VPN toolkit) to replace our traditional patient navigator-led CHB management. Since our preliminary data and other studies indicate that text messaging (TM) interventions have potential to significantly improve adherence to treatment across illnesses, we propose to test the effectiveness of TM versus enhanced mHealth intervention (VPN Toolkit + TM) designed to help sustain and improve long-term adherence (i.e., 24 months follow ups) to monitoring and antiviral treatment guidelines, thereby reducing cancer health disparities among underserved at-risk Asian Americans with CHB leveraging our existing cohort of CHB patients. The specific aims are: 1) Evaluate the comparative effectiveness of TM vs VPN+TM for improving long-term adherence to monitoring (doctor visit and blood tests) every six months (6- , 12-, 18-, and 24-month follow-ups) and ultrasound (at 12 and 24 months); 2) Compare the effectiveness of TM vs VPN+TM in improving and sustaining medication adherence (measured through self-report and electronic monitoring) among Asian Americans with CHB who meet antiviral treatment guidelines; 3) Examine mediators of intervention effectiveness, including dose-response (i.e., utilization of the TM and VPN toolkit), information (knowledge), motivation, and self-efficacy. Our comparative study of mHealth approaches will demonstrate how technology-based interventions can be integrated most effectively into real-world clinical settings to reduce HBV-related liver cancer disparities. If effective, this VPN+TM intervention is a highly disseminable intervention with the potential to have a significant impact on reducing viral-related cancer disparities among underserved Asian Americans and other highest-risk populations.
项目总结 完整研究项目1--肝癌 服务不足的慢性乙肝亚裔美国人长期坚持监测/治疗 TU fccc:Grace X.Ma博士(联席领导)和Nestor Esnaola医学博士,公共卫生硕士(URM ESI联席领导) HC:Sarit A.Golub博士(联席主管)和Chibuzo Enemchukwu医学博士(URM ESI联席主管) 虽然亚裔美国人占美国总人口的6%,但他们占美国人口总数的50%以上 慢性乙型肝炎(CHB),与75%的肝细胞癌(肝细胞癌)有关,这是最常见的 一种类型的肝癌。亚裔美国人作为肝癌差异人群的可能性是其他人群的8-13倍 罹患肝癌的死亡率比非西班牙裔白人(NHW)高60%。研究表明, 每六个月进行一次血液检查,每12个月进行一次腹部超声波检查,同时进行抗病毒治疗 (如恩替卡韦或替诺福韦)在适当的情况下,是降低肝病风险的黄金护理标准 (包括肝癌)。然而,亚裔美国人遵守监测和抗病毒治疗指南 慢性乙肝患者低至40%至53%。较差的医疗保健机会和重大的文化障碍可能 防止长期坚持监测和最佳治疗,将亚裔美国人置于 高得不成比例的肝癌风险和增加的医疗成本。建立在先前对患者的研究基础上 导航员主导的干预措施,以改善对不符合条件的慢性乙肝亚裔美国人的监测和护理, 由我们建立的学术-临床-社区研究团队领导,我们开发并试行了一种 虚拟患者导航工具包系统(VPN工具包)取代我们传统的以患者导航员为主导的CHB 管理层。因为我们初步数据和其他研究表明,短信(TM)干预 有可能显著提高跨疾病治疗的依从性,我们建议测试 TM与增强型mHealth干预(VPN工具包+TM)的有效性旨在帮助维持和 改善对监测和抗病毒治疗指南的长期遵守(即24个月的跟踪), 从而减少未得到充分服务的高危亚裔美国人中的癌症健康差异,利用CHB杠杆 我们现有的CHB患者队列。具体目标是:1)评价TM的相对有效性 VS VPN+TM,提高每六个月监测(就诊和验血)的长期依从性(6- 、12个月、18个月和24个月的随访)和超声(12个月和24个月);2)比较 TM与VPN+TM在改善和维持服药依从性方面(通过自我报告和 电子监测)在符合抗病毒治疗指南的慢性乙肝亚裔美国人中;3)检查 干预效果的介体,包括剂量-反应(即TM和VPN工具包的使用), 信息(知识)、动机和自我效能。我们对移动健康方法的比较研究将 演示基于技术的干预如何最有效地集成到现实世界的临床中 减少与乙肝病毒相关的肝癌差异的设置。如果有效,这种VPN+TM干预是一种高度 有可能对减少病毒相关癌症产生重大影响的可传播干预措施 未得到充分服务的亚裔美国人和其他高危人群之间的差距。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GRACE X. MA其他文献

GRACE X. MA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GRACE X. MA', 18)}}的其他基金

Impact of Structural Racism and Discrimination on Liver Disease Disparities in High-Risk Asian American Populations
结构性种族主义和歧视对高危亚裔美国人肝病差异的影响
  • 批准号:
    10474736
  • 财政年份:
    2022
  • 资助金额:
    $ 24.89万
  • 项目类别:
Impact of Structural Racism and Discrimination on Liver Disease Disparities in High-Risk Asian American Populations
结构性种族主义和歧视对高危亚裔美国人肝病差异的影响
  • 批准号:
    10633201
  • 财政年份:
    2022
  • 资助金额:
    $ 24.89万
  • 项目类别:
MARC at Temple University
天普大学 MARC
  • 批准号:
    10625346
  • 财政年份:
    2020
  • 资助金额:
    $ 24.89万
  • 项目类别:
MARC at Temple University
天普大学 MARC
  • 批准号:
    10405080
  • 财政年份:
    2020
  • 资助金额:
    $ 24.89万
  • 项目类别:
Unpacking the Mechanisms of Disparities for HIV-related Hypertension in African American and Asian Pacific American MSM
揭示非裔美国人和亚太裔 MSM 中 HIV 相关高血压差异的机制
  • 批准号:
    9897219
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10251231
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:
Unpacking the Mechanisms of Disparities for HIV-related Hypertension in African American and Asian Pacific American MSM
揭示非裔美国人和亚太裔 MSM 中 HIV 相关高血压差异的机制
  • 批准号:
    10349449
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:
Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic HBV
服务不足的亚裔美国人慢性乙型肝炎患者长期坚持监测/治疗
  • 批准号:
    10251232
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:
Planning and Evaluation Core
规划与评估核心
  • 批准号:
    10757262
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:
Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic HBV
服务不足的亚裔美国人慢性乙型肝炎患者长期坚持监测/治疗
  • 批准号:
    10462705
  • 财政年份:
    2018
  • 资助金额:
    $ 24.89万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 24.89万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 24.89万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 24.89万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 24.89万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 24.89万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 24.89万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 24.89万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 24.89万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 24.89万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 24.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了